PNT2258
Phase 2- Indications
- Diffuse large B-cell lymphoma, Richter's transformed chronic lymphocytic leukemia, Non-Hodgkin's lymphoma
Company intelligence / Profile preview
Ren-Pharm International, Ltd.
Jericho, New York, United Statesren-pharm.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Not applicable (company is a service provider, not developing clinical programs)
- Industry
- Consulting
02
Drug pipeline
1 asset03
Partnerships
Represents various API suppliers (specific names not provided)
Beyond the preview
Go deeper on Ren-Pharm International, Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ren-Pharm International, Ltd..